Small bruises, under 2.5 cm wide, are common and disappear in a week or two
With the stock already well above both analyst targets and estimated fair value, price volatility and execution risk around GLP-1 and new markets are key issues to keep on your checklist.
Ready to determine your best path
With the wild success of glucagon-like peptide-1 (GLP-1) drugs, Amylyx Pharmaceuticals is looking to explore the field as it has bought out avexitide, a Phase III ready GLP-1 receptor antagonist, for $35 million in an auction last month from bankrupt Eiger BioPharmaceuticals
You are losing the GIP receptor activation that contributed to tirzepatide's effects
This is the largest and most diverse real-world study, comprising 10,328 people of an under-represented population